Zevra Therapeutics Inc (ZVRA)’s Market Momentum: Closing Strong at 8.66, Up 1.05

Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Zevra Therapeutics Inc’s stock clocked out at $8.66, up 1.05% from its previous closing price of $8.57. In other words, the price has increased by $1.05 from its previous closing price. On the day, 1.37 million shares were traded. ZVRA stock price reached its highest trading level at $8.8 during the session, while it also had its lowest trading level at $7.8401.

Ratios:

To gain a deeper understanding of ZVRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.00. In the meantime, Its Debt-to-Equity ratio is 1.83 whereas as Long-Term Debt/Eq ratio is at 1.81.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $20.

On September 24, 2024, Maxim Group reiterated its Buy rating and also lowered its target price recommendation from $18 to $25.

On September 24, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $17.JMP Securities initiated its Mkt Outperform rating on September 24, 2024, with a $17 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when Watton Corey Michael bought 500 shares for $7.92 per share. The transaction valued at 3,958 led to the insider holds 1,500 shares of the business.

Clifton R. LaDuane bought 2,000 shares of ZVRA for $13,540 on Jul 17 ’24. The CFO & Treasurer now owns 18,469 shares after completing the transaction at $6.77 per share. On Jul 16 ’24, another insider, Anderson Thomas, who serves as the Director of the company, bought 10,000 shares for $6.81 each. As a result, the insider paid 68,065 and bolstered with 20,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 455670144 and an Enterprise Value of 431499968. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.99 while its Price-to-Book (P/B) ratio in mrq is 11.20. Its current Enterprise Value per Revenue stands at 17.62 whereas that against EBITDA is -5.309.

Stock Price History:

Over the past 52 weeks, ZVRA has reached a high of $9.09, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 8.68%, while the 200-Day Moving Average is calculated to be 38.64%.

Shares Statistics:

It appears that ZVRA traded 854.92K shares on average per day over the past three months and 621830 shares per day over the past ten days. A total of 52.62M shares are outstanding, with a floating share count of 52.30M. Insiders hold about 0.61% of the company’s shares, while institutions hold 34.51% stake in the company. Shares short for ZVRA as of 1730332800 were 3937545 with a Short Ratio of 4.61, compared to 1727654400 on 4739350. Therefore, it implies a Short% of Shares Outstanding of 3937545 and a Short% of Float of 7.510000499999999.

Most Popular